BANK VONTOBEL/PUT/ROCHE GS/220/0.1/20.09.24 Share Price

Warrant

DE000VM3AJ69

Delayed Deutsche Boerse AG 18:41:59 28/06/2024 BST
0.165 EUR +3.12% Intraday chart for BANK VONTOBEL/PUT/ROCHE GS/220/0.1/20.09.24
1 month-71.55%
3 months-76.76%
Date Price Change
28/06/24 0.165 +3.13%
27/06/24 0.16 -7.51%
26/06/24 0.173 +17.69%
25/06/24 0.147 +5.76%
24/06/24 0.139 -15.76%

Delayed Quote Deutsche Boerse AG

Last update June 28, 2024 at 06:41 pm

More quotes

Static data

Product typeWarrants
Buy / SellPUT
Underlying ROCHE HOLDING AG
IssuerLogo Issuer Vontobel Vontobel
WKN VM3AJ6
ISINDE000VM3AJ69
Date issued 03/10/2023
Strike 220 CHF
Maturity 20/09/2024 (82 Days)
Parity 10 : 1
Emission price 0.76
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 1.44
Lowest since issue 0.138
Delta-0.11x
Omega 17.44
Premium12.58x
Gearing153.61x
Moneyness 0.8807
Difference Strike -30.15 CHF
Difference Strike %-13.70%
Spread 0.01
Spread %5.78%
Intrinsic value 0.000000

Company Profile

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Sector
-
More about the company

Ratings for Roche Holding AG

Trading Rating
Investor Rating
ESG Refinitiv
A+
More Ratings

Consensus: Roche Holding AG

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
20
Last Close Price
249.5 CHF
Average target price
278.1 CHF
Spread / Average Target
+11.44%
Consensus